This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of Rivaroxaban 2.5mg tablets (Xarelto®▼) following specialist initiation for preventing adverse outcomes after acute management of acute coronary syndrome in accordance with NICE TA335.
The Pan Mersey Area Prescribing Committee recommends the prescribing of RIVAROXABAN 2.5mg tablets (Xarelto®▼) plus aspirin, for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events, in accordance with NICE TA607.